Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bimatoprost 0.01% vs Lumigan in Glaucoma/OHT
NCT05401357Phase 3Recruiting
- Sponsor
- Amneal Pharmaceuticals, Inc.
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of bimatoprost in open-angle glaucoma (OAG), ocular hypertension, sponsored by Amneal Pharmaceuticals, Inc.. Started Jun 2022; status: recruiting.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT05401357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05401357.